Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

Executive Summary

New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.

You may also be interested in...



FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace

US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Prioritizing ANDAs entering markets with fewer than three approved generics not expected to become a major advantage until first-cycle clearances increase.

Generic Industry Consolidating But Still Mysterious

Nearly 2,000 ANDAs remain unclaimed as US FDA begins fee calculations for GDUFA II.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB002105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel